Bifogade filer
PDF
Kurs
+15,34%
Kurs
+15,34%
Open
262,20
High
284,20
Low
251,80
Close
284,20
Kursutveckling under dagen för detta pressmeddelande
(SEK).
Likviditet
96,8 MSEK
Likviditet
96,8 MSEK
Rel. mcap
0,45%
Antal aktier
354 142
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2026-01-29 | 08:00 | Bokslutskommuniké 2025 |
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-30 | - | X-dag ordinarie utdelning VITR 1.10 SEK |
| 2025-04-29 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2022-04-27 | - | Årsstämma |
| 2022-04-22 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-16 | - | X-dag ordinarie utdelning VITR 0.00 SEK |
| 2020-06-15 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-11-06 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-03 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2019-05-02 | - | Årsstämma |
| 2019-04-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-06 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | Split VITR 1:5 |
| 2018-04-27 | - | X-dag ordinarie utdelning VITR 3.70 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-02 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | X-dag ordinarie utdelning VITR 2.60 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-03 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-20 | - | Kapitalmarknadsdag 2016 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | X-dag ordinarie utdelning VITR 2.40 SEK |
| 2016-04-28 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-05 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-14 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-06 | - | X-dag ordinarie utdelning VITR 1.50 SEK |
| 2015-05-05 | - | Årsstämma |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-06 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Analytiker möte 2014 |
| 2014-11-06 | - | Kapitalmarknadsdag 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2014-05-05 | - | Årsstämma |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-11-11 | - | Kapitalmarknadsdag 2013 |
| 2013-11-07 | - | Analytiker möte 2013 |
| 2013-11-07 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-12 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-30 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2013-04-29 | - | Årsstämma |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Analytiker möte 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-24 | - | Extra Bolagsstämma 2012 |
| 2012-07-13 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-20 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2012-04-19 | - | Årsstämma |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-07 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-14 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2011-04-27 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-09 | - | Bokslutskommuniké 2010 |
| 2010-11-02 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-15 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-27 | - | X-dag ordinarie utdelning VITR 0.50 SEK |
| 2010-04-27 | - | Kvartalsrapport 2010-Q1 |
| 2010-04-26 | - | Årsstämma |
| 2010-02-05 | - | Bokslutskommuniké 2009 |
| 2009-11-03 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-28 | - | X-dag ordinarie utdelning VITR 0.40 SEK |
| 2009-04-27 | - | Årsstämma |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-07-15 08:00:00
Second quarter
- Sales of SEK 829 (382) million, corresponding to an increase of 117% in SEK, whereof currency effect 18%, acquired growth 80% and organic growth 18%.
- Consumables increased sales by 24% in SEK, Technologies by 37% in SEK, and Genetic Services contributed sales of SEK 341 million.
- Strong growth in all market regions. Americas 241%, EMEA 53%, Japan Pacific 85% and Asia 73% in local currencies.
- Operating income before depreciation and amortisation (EBITDA) was SEK 273 (134) million, corresponding to a margin of 32.9% (35.2%). EBITDA per share increased by 63%.
- Net income was SEK 130 (86) million, resulting in earnings per share of SEK 0.96 (0.79).
- Sales, adjusted for business related to Covid-19 tests, increased by 24% in SEK, and 14% in local currencies.
- EBITDA margin of 32.9% (32.8%).
- Sales of SEK 1,581 (761) million, corresponding to an increase of 108% in SEK, whereof currency effect 16%, acquired growth 77% and organic growth 15%.
- Consumables increased sales by 25% in SEK, Technologies by 18% in SEK, and Genetic Services contributed sales of SEK 645 million.
- Strong growth in all market regions. Americas 247%, EMEA 68%, Japan Pacific 48% and Asia 45% in local currencies.
- Operating income before depreciation and amortisation (EBITDA) was SEK 501 (297) million, corresponding to a margin of 31.7% (39.1%). EBITDA per share increased 35%.
- Net income was SEK 213 (205) million, resulting in earnings per share of SEK 1.56 (1.88).
- Sales, adjusted for business related to Covid-19 tests, increased by 21% in SEK, and 12% in local currencies.
- EBITDA margin of 31.7% (33.6%).
Gothenburg, July 15, 2022
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, phone: +46 31 721 80 01
Patrik Tolf, CFO, phone: +46 31 766 90 21
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on July 15, 2022.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.